Posted on 10/27/2009 12:37:31 PM PDT by khnyny
Critics are calling it a two-tier health system — one for the politically well-connected, another for the hoi polloi. As Germany launched its mass vaccination program against the H1N1 flu virus on Monday, the government found itself fending off accusations of favoritism by offering one vaccine believed to have fewer side effects to civil servants, politicians and soldiers, and another potentially riskier vaccine to everyone else. The government had hoped that Germans would rush to health clinics to receive vaccinations against the rapidly spreading disease, but the rising anger over the different doses may now cause many people to shy away.
Amid growing fears over a possible global flu pandemic, the German government prepared for its mass vaccination campaign earlier this year by ordering 50 million doses of the Pandemrix vaccine, which would be enough for a double dose for 25 million people, around a third of the population. The vaccine, manufactured by GlaxoSmithKline, contains an immune-enhancing chemical compound, known as an adjuvant, whose side effects are not yet entirely known. Then, after a report was leaked to the German media last week, the Interior Ministry confirmed that it had ordered a different vaccine, Celvapan, for government officials and the military. Celvapan, which is made by the U.S. pharmaceutical giant Baxter, does not contain an adjuvant and is believed to have fewer side effects than Pandemrix.
(Excerpt) Read more at time.com ...
Thanks, but I can’t get the link to work...?
Neither Celvapan nor Pandemrix are available in the United States. No 2009 H1N1 vaccination in the United States contains adjuvants. Some people are using this story about Germany to spread irrational fear about conditions in the United States.
Ok. Do you have a link that supports your staements? Thanks.
When they add adjuvant to a vaccine it allows them to use less antigen per dose. These adjuvants have also been linked to many bad side effects.
The amount of vaccine that can be made is limited by the amount of antigen (virus) that is available. The virus (antigen) is grown in eggs and it takes time to grow and purify it for use in the vaccine. A company can make more vaccine, using less antigen, when adjuvant is added.
To put it another way, it is cheaper and faster for them to mass produce a vaccine with adjuvant than without. The peons get the cheap stuff.
Some questions that imho, should be asked:
1. When and how much Celvapan has been produced by Baxter?
2. How does the Baxter vaccine differ from the other H1N1 vaccines?
3. Which H1N1 vaccines have been FDA approved?
4. Who bought the Celvapan?
5. When did they purchase the Celvapan and how much/in what quantities?
Swine H1N1 antigen/adjuvant bait and switch?
| Pandemic Shot May Be Available as Early as September (Update1) By Tom Randall July 29 (Bloomberg) -- A swine flu vaccine may be ready as soon as September, earlier than the mid-October estimate previously reported, with 40 million doses available for distribution first and 80 million more shots ready in October, U.S. health officials said. Yields of antigen, the key vaccine ingredient, have increased and that should ease pressure on vaccine manufacturers, said Robin Robinson, chief of the Biomedical Advanced Research Development Authority, the U.S. agency in charge of buying the vaccine. Vaccine makers previously reported antigen yields 50 percent to 75 percent less than that of the typical seasonal flu shot. About 182 million doses have been purchased by the U.S., and 20 million doses of antigen have already been produced, Robinson told doctors and scientists at a vaccine meeting at the U.S. Centers for Disease Control and Prevention in Atlanta today. Tests to determine safety and proper dosage are continuing. “We’re starting to see for the first time increases in production yields -- we’re able to get a virus that grows well in eggs,” Robinson said at the CDC. “We want to be prepared for the worst-case scenario.” Some members of the CDC’s vaccine panel said that even if the shots were available in September or early October, testing wouldn’t be completed until the end of September, making it difficult to make recommendations for early distribution. Mothers First The CDC’s Advisory Committee on Immunization Practices met today to vote on who should to get the shot the first in case of vaccine shortages. The priority recommendation might never be used if the 120 million shots are available in October as projected, the panel said. The recommendations may also change, depending on the availability of the vaccine and the severity of the outbreaks when the shots first become available. If there is a shortage, pregnant women should be at the front of the list, the panel agreed. About one in eight people who died after contracting the virus have been pregnant women, according to a study published today in the medical journal Lancet. Swine flu in pregnancy warrants immediate treatment with antiviral drugs, according to the study. Other target groups for the vaccine include caregivers and household contacts of infants under 6 months old, who don’t qualify for the shot. Health-care personnel and emergency workers also should be vaccinated early, along with children and young adults from 6 months to 24 years old, and those 25 and older who have health conditions that raise their risk. Healthy people ages 25 and older should wait until sufficient vaccine is available, the panel said. People ages 65 and older are at high risk for seasonal flu and should get their yearly flu shots as early as possible, the CDC said. Studies have found that age group has some natural immunity to swine flu and has a lower risk of contracting the new virus. To contact the reporters on this story: Tom Randall in New York at trandall6@bloomberg.net Last Updated: July 29, 2009 16:49 EDT |
| Swine Flu Shot May Rely on Emergency Use of Additives (Update1) By Tom Randall and Gary Matsumoto July 29 (Bloomberg) -- Swine flu vaccine makers may rely on a U.S. emergency declaration to use experimental additives made by GlaxoSmithKline Plc and Novartis AG to boost a limited supply of shots that will be available to fight the pandemic. The ingredients, known as adjuvants, may be added for the first time to flu shots in the U.S. Health officials today are meeting to discuss the additives at the U.S. Centers for Disease Control and Prevention in Atlanta, and to recommend who should receive the limited amount of vaccines drugmakers say they will begin delivering in September or October. The U.S. Health and Human Services Department declared a public health emergency over swine flu in April, and the Food and Drug Administration has the power to allow the use of unapproved medical products during such a crisis. The U.S. has been slow to approve the use of adjuvants because of safety concerns, and for fear of giving Americans an excuse to avoid getting the shots, said John Treanor, a University of Rochester researcher. “The question is, do you really feel comfortable throwing this new thing into the mix and do you really need to?” said Treanor, a professor of medicine, microbiology and immunology at the school in Rochester, New York. “I myself, if I had to do it, would really wrestle with that decision.” The CDC agreed to pay London-based Glaxo and Novartis, based in Basel, Switzerland, more than $415 million for adjuvants that could be added to the swine flu vaccines, according to a July 13 statement. Early Production Adjuvants may not be necessary if enough shots can be produced without them, according to Health and Human Services. That possibility got a boost today from authorities at the CDC, who said 40 million shots of unadjuvanted vaccine may be available in September, earlier than previously reported, with 80 million more doses ready in October. A safety concern was raised in 2004 when researchers at the University of Florida in Gainesville reported that mice injected with oils used in the adjuvants developed conditions of the type that occur when the body’s immune system produces an excessive protective reaction. Similar reactions haven’t been seen in humans. MF59, made by Novartis and sold in Europe, has been given to more than 40 million people, mostly adults, to prevent seasonal flu, according to the company. Glaxo’s adjuvant has proven safe and effective in clinical trials with 39,000 people, said Lisa Behrens, a spokeswoman for the company, in an e-mail. Glaxo will conduct more studies and continue to monitor safety after the vaccines are in use, she said. Emergency Authorization Under the U.S. health emergency, the FDA may authorize the use of unlicensed vaccines, according to Peper Long, an agency spokeswoman. The FDA convened an advisory committee July 23 to consider what trials are necessary for the vaccines’ approval. Advisory committees consist of medical experts who provide guidance to the agency. Swine flu’s full force may reach the U.S. earlier than the typical flu season, according to the CDC. Vaccine makers are racing to make shots by mid-October, when cases are expected to rise in the northern hemisphere, fueled by cooler temperatures and the return of pupils to close quarters of classrooms. The World Health Organization, based in Geneva, has said the H1N1 influenza, as the pandemic flu is known, is moving with “unprecedented speed.” The flu spread farther globally in less than six weeks than previous pandemics have in more than six months, the Geneva-based agency said on its Web site on July 17. Global health authorities have stopped counting the number of cases and the CDC says more than 1 million people Americans have been sickened by the virus. Egg Yields The vaccine makers have found it difficult to cultivate the quantities of virus needed for vaccine, as the strain yields 50 percent to 75 percent less antigen, the substance that induces immunity, compared with a typical seasonal flu strain, according to the WHO. The virus didn’t initially grow well in eggs, the principal medium used by the industry, vaccine makers said. In the last week, scientists have been able to improve yields in eggs for the first time, which should ease pressure on manufacturers, Robin Robinson, chief of the Biomedical Advanced Research Development Authority, the U.S. agency in charge of buying the vaccine, said today. A decision on adjuvant use hasn’t been made, he said. Mixing Oil, Water The adjuvants are mixes of oil and water that -- by stimulating the immune system -- offer a way to boost the body’s response to antigen. Adjuvants, whose effectiveness vary by flu strain, may boost the strength of the antigen as much as 10- fold, as was the case with a bird flu vaccine approved in Europe, said Treanor, of the University of Rochester. By adding an adjuvant the same amount of antigen can be used to treat more people, he said. “Until GlaxoSmithKline and Novartis can show me it won’t harm a rat or guinea pig, I think it’s a bad idea to give it to humans,” Vicky Debold, a registered nurse with a Ph.D. in public health, who is a member of the FDA’s advisory committee for reviewing vaccines, said July 27 in an interview. The U.S. never had to consider the risks of an adjuvant because regular flu vaccines were deemed to have “worked so tremendously well,” said Lone Simonsen, research director in the department of global health at George Washington University in Washington. “We have had a safe experience with the MF59-adjuvanted vaccine in Italy and Spain for many years now,” Simonsen said. “That experience we can lean on. That’s going to be the best data we have in time for using adjuvanted vaccines.” U.S. Contracts CSL Ltd., which has a $180 million order to supply bulk H1N1 antigen to the U.S. government, decided against boosting its vaccine with an adjuvant, preferring to use a formulation more closely resembling the seasonal flu shot, said Mary Sontrop general manager of the Melbourne-based company’s biotherapies unit. The U.S. has contracts with five companies to provide flu shots. Novartis, based in Basel, Switzerland, is responsible for 45 percent of the supply, while Sanofi will provide 26 percent and CSL will make 19 percent, said Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases in Bethesda, Maryland, in an interview last week. The remaining doses will be made by Glaxo and London-based drugmaker AstraZeneca Plc. To contact the reporters on this story: Tom Randall in New York at trandall6@bloomberg.net; Gary Matsumoto in New York at gmatsumoto@bloomberg.net. Last Updated: July 29, 2009 13:25 EDT |
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.